K

    Kazia Therapeutics Ltd ADR (KZIA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.77
    +0.19 (+1.40%)

    Market Cap: $155.18M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(1/4)
    Avg Surprise
    -18100.63%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-0.00
    Range$-0.00 - $-0.00
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.00
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-0.00---
    Dec 25
    		$-0.58$-0.01-8205.17%Miss+98.1%
    Sep 25
    		$-7.64N/A+96.54%Beat+39.0%
    Jun 25
    		$-4.18$-0.01-64264.62%Miss+86.9%
    Mar 25
    		$-12.30$0.00N/AMiss+59.7%
    Sep 24
    		$-31.22$0.00N/AMiss+13.9%
    Dec 23
    		$-12.53$0.00N/ABeat-114.0%
    Dec 22
    		$-31.86$-24.65-29.27%Miss-530935.0%
    Jun 22
    		$-30.53N/AN/ABeat-500434.4%
    Dec 21
    		$-36.25N/AN/ABeat-158875.4%
    Jun 21
    		$-5.85N/AN/ABeat-27512.7%
    Mar 21
    		$-0.01$0.00N/AMiss+78.7%
    Dec 20
    		$-0.01$0.00N/AMiss+75.7%
    Sep 20
    		$-0.02$0.00N/AMiss+27.6%
    Jun 20
    		$-0.02$0.00N/AMiss+30.0%
    Mar 20
    		$-0.03$0.00N/AMiss-17.5%
    Dec 19
    		$-0.03$0.00N/AMiss-3.3%
    Sep 19
    		$-0.03$0.00N/AMiss+21.4%
    Jun 19
    		$-0.03$0.00N/AMiss+26.5%
    Mar 19
    		$-0.02$0.00N/AMiss+51.4%
    Dec 18
    		$-0.02$0.00N/AMiss-343.0%
    Sep 18
    		$-0.04$0.00N/AMiss-1279.4%
    Jun 18
    		$-0.04$0.00N/AMiss+68.3%
    Mar 18
    		$-0.05$0.00N/AMiss+4.3%
    Dec 17
    		$0.01$0.00N/ABeat+111.1%
    Sep 17
    		$0.00$0.00N/ABeat+101.8%
    Jun 17
    		$-0.13$0.00N/AMiss-
    Mar 17
    		$-0.05$0.00N/AMiss-
    Dec 16
    		$-0.09$0.00N/AMiss-
    Sep 16
    		$-0.19$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.56EV/EBITDA-0.71x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-14641.00%
    ROE-106.90%ROIC-77.39%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.87xQuick Ratio2.87x
    Trading Statistics
    Beta2.14Avg Volume264.29K
    52-Week High$17.4052-Week Low$4.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.14
    SMA 20$13.64
    SMA 50$13.48
    SMA 200$10.42
    EMA 10$14.10
    EMA 20$13.81
    EMA 50$13.34
    EMA 200$10.95

    MACD

    Line: 0.34Signal: 0.26Hist: 0.07

    ADX

    ADX: 17.1+DI: 28.4-DI: 18.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$17.10

    Bollinger Bands

    Upper Band$15.69
    Lower Band$11.59
    %B Position3001%(Upper)
    Band Width0.53

    RSI (14-Day)

    Neutral
    50.5

    Momentum Oscillators

    Stoch %K48.1
    Stoch %D65.1
    Williams %R-72.9
    ROC (10d)1.5%
    Momentum0.21
    CCI (20d)11.9
    MFI (14d)44.8

    Volatility Measures

    ATR (14d)$1.30(9.5%)
    StdDev (20d)1.02
    Hist Vol114.4%(High)

    Volume Flow

    VWAP$13.73
    OBV84.9M
    AD Line239.4M
    CMF (20d)-0.014

    Volume Metrics

    Avg Vol (20d)267.6K
    Vol Ratio1.4x
    VWMA (20d)$14.07

    Pivot Points

    R3$17.15
    R2$16.33
    R1$14.95
    Pivot Point$14.13
    S1$12.75
    S2$11.93
    S3$10.55

    Advanced Oscillators

    TSI8.74
    Ultimate Osc49.5
    KST77.09

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total RevenueN/A$19,710$19,710$22,290$2.48M$2.48M$5$1,000N/A$278N/AN/A
    Cost of RevenueN/AN/A$0N/AN/A$0N/AN/AN/AN/AN/A$2.90M
    Gross ProfitN/A$19,710$19,710$22,290$2.48M$2.48M$5$1,000N/A$278$-626,204$-671,826
    Operating Expenses$13.30M$6.46M$6.46M$9.39M$22.06M$22.06M$8.88M$10.51MN/A$3.52M$13.64M$25.38M
    R&D$4.90M$2.96M$2.96M$4.28M$13.05M$13.05M$4.33M$6.20M$0$3.10M$9.36M$9.18M
    SG&A$0$0$3.51M$5.11M$9.01M$9.01M$4.56M$4.31M$0$2.15M$4.28M$2.63M
    Operating Income$-13,301,623$-4,848,616$-4,848,616$-9,368,384$-19,578,597$-19,578,597$-8,883,403$-10,509,514N/A$-5,255,021$-13,636,486$-25,382,135
    Interest Income$0$0$42,075$0$0$5,547$0$0$0$0$0$0
    Interest Expense$0$7.01M$0$1.22M$0$0$75,656$0$0$0$85,087$4.44M
    Income Before Tax$-12,322,167$-11,858,643$-11,858,643$-10,589,357$-18,089,941$-18,089,941$-8,959,059$-7,014,427$0$-3,507,349$-13,721,573$-11,864,313
    Income Tax Expense$0$-1,610,454$-1,610,454$-135,546$-135,454$-135,454$-135,546$-135,454$-67,773$67,773$-135,546$-52,106
    Net Income$-12,322,167$-9,951,035$-9,951,035$-10,453,811$-17,954,487$-17,954,487$-8,823,513$-6,878,973N/A$-3,439,576$-13,586,027$-11,812,207
    EBITDA$-13,301,623$-4,848,616$-4,848,616$-8,433,673$-18,644,302$-18,644,302$-7,948,698$-9,575,255N/A$-4,787,662$-12,701,745$-11,003,819
    EBITN/A$-4,848,616$-4,848,616$-9,368,384$-19,578,597$-19,578,597$-8,883,403$-10,509,514$-5,255,021$-5,255,021$-13,636,486$-11,938,528
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KZIA

    News

    Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake

    Investor Jorey Chernett has filed an amended Schedule 13G/A, disclosing beneficial ownership of 2,339,009 American Depositary Shares (ADS) of KAZIA THERAPEUTICS LTD (NASDAQ: KZIA). This stake represents 19.6% of the company's outstanding ADS as of August 19, 2026. Chernett reports having sole voting and dispositive power over these shares, indicating significant control over his investment in Kazia.

    Stock Titan•8/19/26•
    Neutral

    Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap

    Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 575,778 American Depositary Shares (ADSs) of Kazia Therapeutics Limited (KZIA), which constitutes 4.9% of the total ADS class. This figure includes 179,577 ADSs acquirable within 60 days via warrants, subject to a 4.99% beneficial ownership limitation. The calculation is based on 11,515,568 total ADSs, comprising outstanding shares and those issuable through warrant exercise.

    Stock Titan•8/15/26•
    Neutral

    CCORF Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $29

    CCORF has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating and set a price target of $29. This new rating suggests a positive outlook for the company's stock from CCORF.

    Moomoo•8/15/26•
    Bullish

    Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS

    Lynwood Opportunities Master Fund, Lynwood Capital Management Inc., and Ben Shapiro have reported a beneficial ownership of 4.6% in Kazia Therapeutics (KZIA) through American Depositary Shares as of June 30, 2026. This stake represents 264,980,500 Ordinary Shares, with each ADS equivalent to 500 Ordinary Shares. The reporting persons assert sole voting and dispositive power and disclaim beneficial ownership beyond their directly held shares, confirming their ownership is below the 5% threshold.

    Stock Titan•8/14/26•
    Neutral

    KZIA Initiates Coverage On by Canaccord Genuity -- Price Target Announced at $29

    Canaccord Genuity has initiated coverage on Kazia Therapeutics (KZIA) with a 'Buy' rating and a price target of $29.00, significantly higher than its current market price of $13.09. Despite this positive analyst outlook and strong momentum, the company holds a low GF Score™ of 33/100, indicating profitability and valuation concerns due to its unprofitable status and high Price-to-Sales ratio. Limited institutional interest and insider activity suggest caution for investors considering the inherent risks of this biotechnology firm.

    GuruFocus•8/13/26•
    Bullish

    Frequently Asked Questions About KZIA

    Does KZIA pay dividends?
    Kazia Therapeutics Ltd ADR (KZIA) does not currently pay a regular dividend.
    What is KZIA's market cap?
    Kazia Therapeutics Ltd ADR (KZIA) has a market capitalization of $155.18M with a current stock price of $13.77.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In